About this event
- Date and time Tue 12 Dec 2023 from 9:00am to 5:00pm
- Location Royal Society of Medicine
- Organised by Vascular, Lipid and Metabolic Medicine Section
Join us in this meeting for an updated overview of genetic dyslipidaemias, enabling participants to learn how to recognize, test and treat them. Reduced fees for trainees and students.
This one-day meeting will be divided into three sections with invited speakers chosen for their expertise in the area.
- Session One will cover the genetic basis of hypercholesterolaemia. There will be a focus on monogenic Familial Hypercholesterolaemia, and covering how understanding its diverse genetic basis has informed new treatments for cholesterol lowering. Polygenic hypercholesterolaemia will also be discussed, with a review of the current status of genetic testing. It will end with a summary of our current understanding of the atherogenic role of Lipoprotein(a), when to test for it and how to manage patients with elevated levels
- Session Two will cover the genetic basis of hypertriglyceridaemia. It will cover the growing understanding of abnormal triglyceride metabolism's genetic and metabolic basis and how this is expanding the current limited range of treatments for elevated triglyceride levels
- Session Three will cover a number of rare monogenic dyslipidaemias including Tangier Disease and Sitosterolaemia
By attending this event, you will be able to:
- Distinguish between monogenic and polygenic hypercholesterolaemia, recognize their contribution to cardiovascular risk and know the treatments available
- Understand the genetic causes of hypertriglyceridaemia, their complications and current and proposed treatments
- Learn about some other rare monogenic dyslipidaemias
Follow us on:
Facebook
Instagram
LinkedIn
Twitter
YouTube
We would like to thank our sponsors Amgen, Novartis, Sanofi, Sobi and Ultragenyx for their support of this event. Please note that the main scientific programme and content has not been influenced in any way by the sponsors.
Show Virtual / In Person rates
Agenda
View the programme (in-person)
Registration, tea and coffee
Welcome and introduction
Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust and Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Session 1: Genetic Hypercholesterolaemia
Chairs: Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust and Professor Steve Humphries, Professor in Cardiovascular Genetics, University College London Hospitals NHS Foundation Trust
Monogenic Familial Hypercholesterolaemia (FH)
Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Polygenic Hypercholesterolaemia
Professor Steve Humphries, Professor in Cardiovascular Genetics, University College London Hospitals NHS Foundation Trust
Lipoprotein (a)
Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust
Disrupting the care of cardiovascular disease with single-course gene editing medicines
Dr Scott Vafai, Vice President, Translational Medicine, Verve Therapeutics
Panel discussion
Lunch break
Session 2: Genetic Hypertriglyceridemia
Chairs: Professor Andrew Krentz, President, Vascular, Lipid and Metabolic Medicine Section, Royal Society of Medicine and Dr Abdul Lakhdar, President, Endocrinology & Diabetes Section, Royal Society of Medicine
Familial Chylomicronaemia Syndrome
Dr Handrean Soran, Endocrinologist, Manchester University NHS Foundation Trust
Type 3 Hyperlipoproteinemia
Professor Paul Durrington, Professor of Medicine, Manchester University NHS Foundation Trust
The patient with Lipodystrophy: Finding the needle in a haystack
Dr Rachel Williams, Consultant Paediatric Diabetologist & Endocrinologist, Addenbrooke's Hospital, Cambridge
Panel discussion
Tea and coffee break
Session 3: Rare genetic dyslipidaemias
Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust and Dr Handrean Soran, Endocrinologist, Manchester University NHS Foundation Trust
Lysosomal Acid Lipase Deficiency
Dr Patrick Deegan, Consultant Metabolic Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Lecithin Cholesterol Acyl Transferase (LCAT) deficiency
Dr Ben Jones, Consultant, Metabolic Medicine, Imperial College Healthcare NHS Trust
Abetalipoproteinaemia and Hypobetalipoproteinaemia
Dr Paul Downie, Consultant Medical Biochemist, University Hospitals Bristol NHS Foundation Trust
Sitosterolaemia
Dr Radha Ramachandran, Consultant, Adult Inherited Metabolic Disorders, Chemical Pathology, Metabolic Medicine, Guy's and St Thomas' NHS Foundation Trust
Tangier Disease
Dr Charlotte Dawson, Consultant, Metabolic Medicine, University Hospitals Birmingham NHS Foundation Trust
Panel discussion
Closing remarks
Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust and Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Close of meeting
View the programme (virtual)
Welcome and introduction
Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust and Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Session 1: Genetic Hypercholesterolaemia
Chairs: to be confirmed
Monogenic Familial Hypercholesterolaemia (FH)
Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Polygenic Hypercholesterolaemia
Professor Steve Humphries, Professor in Cardiovascular Genetics, University College London Hospitals NHS Foundation Trust
Lipoprotein (a)
Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust
Treating Hypercholesterolaemia genetically
Dr Scott Vafai, Vice President, Translational Medicine, Verve Therapeutics
Panel discussion
Lunch break
Session 2: Genetic Hypertriglyceridemia
Chairs: to be confirmed
Familial Chylomicronaemia Syndrome
Dr Handrean Soran, Endocrinologist, Manchester University NHS Foundation Trust
Type 3 Hyperlipoproteinemia
Professor Paul Durrington, Professor of Medicine, Manchester University NHS Foundation Trust
Lipodystrophy and dyslipidaemia
Speaker to be confirmed
Panel discussion
Comfort break
Session 3: Rare genetic dyslipidaemias
Chairs: to be confirmed
Lysosomal Acid Lipase Deficiency
Dr Patrick Deegan, Consultant Metabolic Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Lecithin Cholesterol Acyl Transferase (LCAT) deficiency
Dr Ben Jones, Consultant, Metabolic Medicine, Imperial College Healthcare NHS Trust
Abetalipoproteinaemia and Hypobetalipoproteinaemia
Dr Paul Downie, Consultant Medical Biochemist, University Hospitals Bristol NHS Foundation Trust
Sitosterolaemia
Dr Radha Ramachandran, Consultant, Adult Inherited Metabolic Disorders, Chemical Pathology, Metabolic Medicine, Guy's and St Thomas' NHS Foundation Trust
Tangier Disease
Dr Charlotte Dawson, Consultant, Metabolic Medicine, University Hospitals Birmingham NHS Foundation Trust
Panel discussion
Closing remarks
Dr Jaimini Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Foundation Trust and Dr Paul Flynn, Consultant Physician, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Close of meeting
Sponsors
Location
Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom
Disclaimers:
Registration for this event will close on 11 December 2023 at 1:00am (GMT). Late registrations will not be accepted.
The agenda is subject to change at any time
All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.
We are only able to share presentations that we have received permission to share. This is at the presenter and the RSM’s discretion.
This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.